Wenyu Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wenyu Wu has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Bo Luo
Center of Drug Discovery, State Key Laboratory of Natural Medicines
2 shared publications- Hai Qian
China Pharmaceutical University
2 shared publications Rui Yang
Nanjing Medical University
2 shared publicationsA Cahid Civelek
Department of Radiology Division of Nuclear Medicine
1 shared publication- Chaowei Hao
China Pharmaceutical University
1 shared publication Fei Yu
Department of Nuclear Medicine, Nanjing First Hospital
1 shared publication
Latest Publications
- 14 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5946-5955
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics
Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
- 14 October 2026
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 23 (11) , 5946-5955
Preclinical Study of the 89Zr/177Lu-Labeled Engineered VHH-based Antibody for CLDN18.2-Targeted Radiotheranostics
Claudin 18.2 (CLDN18.2) is a tight junction protein aberrantly expressed in gastric and pancreatic cancer. In this study, we developed the novel nanobody 18.2−50H and VHH-Fc fusion antibody 18.2−50C radiolabeled with 89Zr/177Lu for CLDN18.2-targeted radiotheranostics. Zolbetuximab (IMAB362), 18.2−50H, and 18.2−50C were conjugated with DFO and labeled with 89Zr, respectively. Radiochemical purity and in vitro stability were determined by radio-TLC. CLDN18.2-targeting specificity was evaluated using HEK-293T and HEK-293T/CLDN18.2 cells. PET/CT imaging and biodistribution studies were performed in mouse models and cynomolgus monkeys. Subsequently, 177Lu-DOTA-18.2-50C was prepared and assessed for tumor targeting in gastric cancer PDX models. 89Zr-DFO-IMAB362, 89Zr-DFO-18.2-50H, and 89Zr-DFO-18.2-50C were prepared with satisfactory radiochemical yield, specific activity, and stability. Tumors were clearly visible as early as 1 h post-injection of 89Zr-DFO-18.2-50H, with an uptake value of 9.07 ± 2.36 %ID/g and a tumor-to-muscle ratio of 27.35 ± 3.72. Fc-fused 89Zr-DFO-18.2-50C exhibited improved retention and higher tumor uptake than 89Zr-DFO-18.2-50H and 89Zr-DFO-IMAB362, with % ID/g increasing continuously from 5.07 ± 0.29 at 1 h to 32.95 ± 1.57 at 168 h. Notably, the introduction of the Fc chain also markedly increased the radiation exposure in the liver and spleen. Consistently, PET imaging in cynomolgus showed that 89Zr-DFO-18.2-50C is mainly concentrated in the liver, but no apparent abnormality was observed. Furthermore, 177Lu-DOTA-18.2-50C presented remarkable tumor selectivity with prolonged retention (16.92 ± 1.94 % ID/g at 5 d post-injection) in PDX models. Nanobody 89Zr-DFO-18.2-50H demonstrated a superior tumor-to-background ratio, positioning it as a promising tracer for detecting CLDN18.2-overexpressing lesions. 89Zr/177Lu-labeled VHH-Fc antibody 18.2−50C exhibited sustained higher tumor uptake than commercially available IMAB362 and provides a novel potential candidate for CLDN18.2-targeted radionuclide therapy.
- 29 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15961-15973
Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers
Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.
- 29 June 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (13) , 15961-15973
Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68 Ga-PET Radiotracers
Triple-negative breast cancer (TNBC) lacks effective molecular targets for imaging. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is overexpressed in the mesenchymal-like (claudin-low) subtype of TNBC. Here, we developed two optimized linear peptide radiotracers, DR1 and DR2, derived from the complementarity-determining regions (CDR) of an anti-ROR1 antibody, conjugated with DOTA and labeled with 68Ga. Both peptides showed nanomolar binding affinities (KD = 93.4 ± 8.2 nM for DR1 and 38.0 ± 4.6 nM for DR2) and favorable target-binding properties. [68Ga]Ga-DOTA-DR2 exhibited excellent in vitro stability (≥95% radiochemical purity after 4 h in human serum), rapid in vivo clearance (t1/2β = 0.66 ± 0.11 h), and specific cellular uptake. Micro-PET/CT imaging in MDA-MB-231 xenograft mice revealed rapid tumor visualization, with a peak tumor uptake of 2.75 ± 0.61 %ID/g at 1 h and a tumor-to-muscle ratio of 7.98 at 2 h. Blocking studies confirmed ROR1-specific targeting. Collectively, [68Ga]Ga-DOTA-DR2 may represent a promising PET tracer for imaging ROR1-positive mesenchymal-like TNBC, providing a foundation for further optimization.
- Open Access
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (20) , 29922-29932
Preclinical and First-In-Human Evaluation of 68 Ga-PSMA-33, a Novel PSMA Radiotracer with Low Background Signal
Purpose: this study aimed to investigate the potential of a novel 68Ga-labeled PSMA-targeted radiotracer, 68Ga-PSMA-33, as a diagnostic tool for prostate cancer in preclinical and pilot clinical studies. Methods: 68Ga-PSMA-33 was radiolabeled using an iQS-TS automated module, and its radiochemical purity and in vitro stability were analyzed via radio-HPLC. The specificity and binding affinity for PSMA were determined in LNCaP (PSMA+) cells. A head-to-head comparison with 68Ga-PSMA-617 was performed in murine models through biodistribution, pharmacokinetic, and micro-PET/CT imaging studies. The clinical phase involved 68Ga-PSMA-33 PET/CT imaging in seven patients with prostate cancer, two of whom also underwent 68Ga-PSMA-617 imaging for direct comparison. Semiquantitative assessment of physiologic biodistribution and tumor burden was conducted, and the radiation dosimetry of 68Ga-PSMA-33 was estimated. Results: 68Ga-PSMA-33 was efficiently prepared with a labeling yield of 77.5 ± 7.23%, radiochemical purity exceeding 99%, and specific activity of 45.28 ± 6.37 GBq/μmol. The labeled compound demonstrated a high affinity for PSMA (0.103 ± 0.03 nM), along with high hydrophilicity (Log P = −2.84 ± 0.13). Micro-PET/CT imaging revealed rapid clearance and prominent tumor uptake of the tracer, achieving a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 (88.85 ± 8.39 vs 30.18 ± 3.39, p < 0.001) at 4 h postinjection. A total of nearly 400 tumor lesions were identified in PET/CT imaging across the 7 patients with prostate cancer. The mean SUVmax values of primary tumors, lymph node metastases, liver metastases, and bone metastases were 22.24 ± 4.77, 10.48 ± 2.16, 21.76 ± 3.82, and 30.25 ± 2.80 at 1 h postinjection, respectively. Clinical 68Ga-PSMA-33 PET/CT studies further confirmed its favorable biodistribution and kinetics, exhibiting a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 at 3 h postinjection in both lymph node metastases (23.64 ± 6.68 vs 17.47 ± 7.53, p < 0.01) and bone metastases (83.33 ± 18.80 vs 61.63 ± 13.26, p < 0.001). The radiation dose of 68Ga-PSMA-33 was within an acceptable range, with an effective dose of (7.38 ± 1.44) × 10–3 mSv/MBq. The kidneys were the critical organ, receiving the highest absorbed dose of (7.35 ± 2.64) × 10–2 mGy/MBq. Conclusion: 68Ga-PSMA-33 demonstrated comparable tumor uptake while providing a higher tumor-to-background ratio and lower radiation exposure than 68Ga-PSMA-617, making it a promising novel tracer for prostate cancer diagnosis.
- 13 May 2026
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 11 (20) , 29922-29932
Open AccessPreclinical and First-In-Human Evaluation of 68 Ga-PSMA-33, a Novel PSMA Radiotracer with Low Background Signal
Purpose: this study aimed to investigate the potential of a novel 68Ga-labeled PSMA-targeted radiotracer, 68Ga-PSMA-33, as a diagnostic tool for prostate cancer in preclinical and pilot clinical studies. Methods: 68Ga-PSMA-33 was radiolabeled using an iQS-TS automated module, and its radiochemical purity and in vitro stability were analyzed via radio-HPLC. The specificity and binding affinity for PSMA were determined in LNCaP (PSMA+) cells. A head-to-head comparison with 68Ga-PSMA-617 was performed in murine models through biodistribution, pharmacokinetic, and micro-PET/CT imaging studies. The clinical phase involved 68Ga-PSMA-33 PET/CT imaging in seven patients with prostate cancer, two of whom also underwent 68Ga-PSMA-617 imaging for direct comparison. Semiquantitative assessment of physiologic biodistribution and tumor burden was conducted, and the radiation dosimetry of 68Ga-PSMA-33 was estimated. Results: 68Ga-PSMA-33 was efficiently prepared with a labeling yield of 77.5 ± 7.23%, radiochemical purity exceeding 99%, and specific activity of 45.28 ± 6.37 GBq/μmol. The labeled compound demonstrated a high affinity for PSMA (0.103 ± 0.03 nM), along with high hydrophilicity (Log P = −2.84 ± 0.13). Micro-PET/CT imaging revealed rapid clearance and prominent tumor uptake of the tracer, achieving a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 (88.85 ± 8.39 vs 30.18 ± 3.39, p < 0.001) at 4 h postinjection. A total of nearly 400 tumor lesions were identified in PET/CT imaging across the 7 patients with prostate cancer. The mean SUVmax values of primary tumors, lymph node metastases, liver metastases, and bone metastases were 22.24 ± 4.77, 10.48 ± 2.16, 21.76 ± 3.82, and 30.25 ± 2.80 at 1 h postinjection, respectively. Clinical 68Ga-PSMA-33 PET/CT studies further confirmed its favorable biodistribution and kinetics, exhibiting a significantly higher tumor-to-muscle ratio than 68Ga-PSMA-617 at 3 h postinjection in both lymph node metastases (23.64 ± 6.68 vs 17.47 ± 7.53, p < 0.01) and bone metastases (83.33 ± 18.80 vs 61.63 ± 13.26, p < 0.001). The radiation dose of 68Ga-PSMA-33 was within an acceptable range, with an effective dose of (7.38 ± 1.44) × 10–3 mSv/MBq. The kidneys were the critical organ, receiving the highest absorbed dose of (7.35 ± 2.64) × 10–2 mGy/MBq. Conclusion: 68Ga-PSMA-33 demonstrated comparable tumor uptake while providing a higher tumor-to-background ratio and lower radiation exposure than 68Ga-PSMA-617, making it a promising novel tracer for prostate cancer diagnosis.